PCOS is now PMOS: Why the name change matters for diagnosis, counseling, and long-term care
Industry Buzz
This condition was never just about cysts on the ovaries. It’s a complex hormonal and metabolic disorder that can affect insulin resistance, weight, fertility, skin, mood, inflammation, cardiovascular health, and so much more.
—Thais Aliabadi, MD
It was heartbreaking to see the delayed diagnosis, limited awareness, and inadequate care afforded those affected by this neglected condition.
—Helena Teede, PhD
For years, clinicians have had to explain to patients with polycystic ovary syndrome (PCOS) that many do not actually have ovarian cysts, and that ovaries are only part of the story.
Now, after more than a decade of international debate, advocacy, and research collaboration, the condition is being renamed polyendocrine metabolic ovarian syndrome (PMOS)—a shift experts say better reflects the disorder’s systemic nature, and that could reshape how physicians discuss diagnosis and risk with patients.[][]
The name change was announced following a 14-year global effort involving some 56 professional and patient organizations. It is expected to be fully incorporated into international guidelines by 2028.[]
Related: Finally, a first step in taking women's health seriouslyWhy experts wanted to retire the term ‘PCOS’
The central problem, according to endocrinologists and patient advocates, is that the old terminology has long misled patients and clinicians.
The term ‘polycystic ovary syndrome’ implies that ovarian cysts define the disease. In reality, many affected patients never develop cystic ovarian morphology, while others without the syndrome may have polycystic-appearing ovaries on imaging. []
Clinicians have also increasingly recognized that the condition extends far beyond reproductive health. Patients may present with insulin resistance, obesity, dyslipidemia, infertility, acne, hirsutism, depression or anxiety, sleep apnea, or elevated cardiometabolic risk, among other conditions.[]
That broader pathophysiology is reflected in the new name:
Polyendocrine acknowledges multisystem hormonal dysfunction
Metabolic highlights insulin resistance and cardiometabolic risk
‘Ovarian’ preserves the reproductive component without centering it exclusively
“This condition was never just about cysts on the ovaries. It’s a complex hormonal and metabolic disorder that can affect insulin resistance, weight, fertility, skin, mood, inflammation, cardiovascular health, and so much more,” said Thais Aliabadi, MD, a board-certified OB/GYN, in an Instagram Reel.
Researchers involved in the renaming effort say the old terminology may have contributed to delayed diagnosis and inadequate care.[]
“It was heartbreaking to see the delayed diagnosis, limited awareness, and inadequate care afforded those affected by this neglected condition. While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition,” endocrinologist Helena Teede, PhD, said in a press release.[]
Global surveys found that most patients and healthcare professionals supported a name change.[]
A diagnostic label that may have obscured disease burden
The move also reflects frustration with persistent underdiagnosis.
Experts estimate the syndrome affects roughly 1 in 8 women globally, yet many cases remain unidentified for years.[]
Part of the issue may stem from how narrowly the condition has been framed. When patients hear "ovary syndrome," they may not connect symptoms such as weight changes, insulin resistance, fatigue, mood symptoms, or dermatologic manifestations to the same underlying disorder.
For clinicians, the new terminology may reinforce the need to think beyond gynecology alone.
The syndrome is associated with []:
Type 2 diabetes risk
Cardiovascular disease risk
Infertility and pregnancy complications
Endometrial cancer risk
Depression and anxiety
Dermatologic manifestations, including acne and androgenic hair changes
Some endocrinologists involved in the initiative argue that the previous name unintentionally minimized the metabolic dimension of the disease and reinforced misconceptions that it was just a fertility issue.
What physicians should tell patients asking, ‘Do I have PCOS?’
For practicing clinicians, the renaming effort may offer a useful opportunity to reset patient expectations about diagnosis. Diagnosis has never depended solely on ovarian cysts.
Patients often arrive believing they cannot have PCOS if imaging is normal, or assuming they do have the condition simply because cysts were seen incidentally on ultrasound. The updated terminology may help correct both misunderstandings.
When counseling patients, physicians can emphasize that diagnosis is based on a constellation of findings that may include:
Ovulatory dysfunction or irregular menses
Clinical or biochemical hyperandrogenism
Polycystic ovarian morphology
Metabolic abnormalities or insulin resistance
Exclusion of competing endocrine disorders
The condition also presents heterogeneously. Some patients primarily struggle with infertility, while others present with acne, hirsutism, obesity, glucose intolerance, or mood symptoms.
That variability is one reason advocates pushed for terminology that reflects a syndrome involving multiple endocrine and metabolic pathways rather than a single ovarian abnormality.
Related: 3 major shifts in women’s health you probably weren't expecting—and can't afford to missThe practical takeaway for clinicians
The new name itself will not change diagnostic criteria overnight. But it may change conversations in the exam room.
For physicians, the transition to PMOS is a reminder to:
Screen broadly for metabolic and cardiovascular risk
Address mental health alongside reproductive symptoms
Avoid reducing the condition to fertility alone
Clarify that ovarian cysts are neither required nor sufficient for diagnosis
Frame the syndrome as a chronic multisystem endocrine disorder
For patients seeking answers, the messaging may become clearer: this is not simply an ovarian condition; it is a complex hormonal and metabolic syndrome that can affect the entire body.